COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis
Open Access
- 17 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 12, 666067
Abstract
As the global burden of mortality from COVID-19 continues to rise, an understanding of who is most at risk of adverse outcomes is of paramount importance. Pre-existing cardiometabolic, renal and respiratory diseases as well as old age are well-established risk factors associated with disease severity and mortality among patients with COVID-19. However, mounting evidence also indicates an increased susceptibility to, and risk of adverse outcomes from COVID-19 in people with schizophrenia, independent of age and comorbidity. Therefore, elucidating the underlying pathophysiological mechanisms which may increase the risk of poor outcomes in people with schizophrenia is of crucial importance. Here, we provide a narrative on the current understanding of COVID-19 in patients with schizophrenia and propose potential mechanisms which may link schizophrenia with an increased susceptibility to, and greater risk of adverse outcomes from COVID-19. Given the existing knowledge gaps, robust clinical and biological studies are required to further our understanding of some of these underlying mechanisms, so that effective prevention and treatment strategies for COVID-19 in patients with schizophrenia can be developed.Keywords
This publication has 118 references indexed in Scilit:
- Association of Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in Young Adult LifeJAMA Psychiatry, 2014
- Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysisSchizophrenia Research, 2014
- Antipsychotic Drug Exposure and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Observational StudiesDrug Safety, 2014
- A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controlsWorld Psychiatry, 2013
- Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature reviewTherapeutic Advances in Psychopharmacology, 2013
- Antipsychotics and Venous Thromboembolism Risk: A Meta-AnalysisPharmacopsychiatry, 2011
- Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relativesSchizophrenia Research, 2008
- The cardiovascular and respiratory health of people with schizophreniaActa Psychiatrica Scandinavica, 2006
- The Poor General Health of the Severely Mentally Ill: Impact of Schizophrenic DiagnosisCommunity Mental Health Journal, 2005
- Consensus Statement: Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesThe Journal of Clinical Psychiatry, 2004